Brazilian billionaire Lemann leads initiative to build COVID-19 vaccine factory




  • In Business
  • 2020-08-07 22:19:20Z
  • By Reuters

SAO PAULO (Reuters) - Brazilian billionaire Jorge Lemann's foundation and other business interests will fund the building of factory to produce the COVID-19 vaccine being developed by Oxford University and pharmaceutical company AstraZeneca PLC.

The Lemann Foundation said in a statement on Friday that the 100 million reais ($18 million) factory will be donated to Brazil's premier biomedical research and development lab, the Oswaldo Cruz Foundation, or Fiocruz.

It said the factory will be ready to produce 30 million doses of the vaccine per month as of the beginning of 2021.

Brazil is approaching 100,000 deaths from COVID-19 in the world's worst coronavirus outbreak after the United States.

The Brazilian government sees the British vaccine as the most promising of the vaccines that are being developed by researchers worldwide.

The Oxford/AstraZeneca vaccine is being tested on Brazilian volunteers in a study led by the Federal University of São Paulo that is also funded by the Lemann Foundation.

Other donors to the initiative to ensure Brazil can absorb the technology to produce the potential vaccine include Brazilian brewer Ambev SA, Itaú Unibanco, the Votorantim Institute and the Behring Family Foundation.

Lemann said he hoped the initiative will help Brazil be "better positioned and prepared to face other challenges of this nature that may arise."

Brazilian President Jair Bolsonaro issued a decree on Thursday setting aside 1.9 billion reais ($356 million) in funds to purchase an initial 100 million doses of the Oxford/AstraZeneca vaccine and to invest in its eventually production in Brazil.

The health ministry reported on Friday 50,230 new cases of the novel coronavirus and 1,079 deaths from the disease caused by the virus in the past 24 hours.

Brazil has registered 2,962,442 cases of the virus since the pandemic began, while the official death toll from COVID-19 has risen to 99,572, according to ministry data.


(Reporting by Eduardo Simoes; Writing by Anthony Boadle; editing by Diane Craft and Marguerita Choy)

COMMENTS

More Related News

Positive results for J&J vaccine; child racial disparities seen
Positive results for J&J vaccine; child racial disparities seen
  • US
  • 2020-09-25 19:49:03Z

A single dose of Johnson & Johnson's experimental COVID-19 vaccine produced a strong immune response against the novel coronavirus, according to interim results from an early-to-mid stage clinical trial released on Friday. The study, backed by the U.S. government, involves about 1,000 adults.

Johnson & Johnson COVID-19 vaccine produces strong immune response in early trial
Johnson & Johnson COVID-19 vaccine produces strong immune response in early trial
  • US
  • 2020-09-25 18:56:18Z

A single shot, versus a rival two-dose approach being tested by Moderna Inc and Pfizer Inc , could simplify distribution of the vaccine. The trial in close to 1,000 healthy adults, which is backed by the U.S. government, began after the J&J vaccine was found in July to offer strong protection in a single dose to monkeys.

What you need to know about the coronavirus right now
What you need to know about the coronavirus right now
  • US
  • 2020-09-25 10:16:48Z

The number of novel coronavirus cases in the United States topped 7 million on Thursday - more than 20% of the world's total - as Midwest states reported spikes in COVID-19 infections in September, a Reuters tally shows. All Midwest states except Ohio reported more cases in the past four weeks as compared with the prior four weeks, led by South Dakota and North Dakota. European governments will pay claims above an agreed limit against AstraZeneca over side-effects from its potential COVID-19 vaccine, under different terms to a deal struck with Sanofi, an EU official told Reuters.

AstraZeneca still waiting for FDA go-ahead to resume U.S. trial
AstraZeneca still waiting for FDA go-ahead to resume U.S. trial

AstraZeneca is still waiting for the U.S. drug regulator to approve the restart of the clinical trial of its potential COVID-19 vaccine in the United States almost three weeks after it was paused due to safety concerns. The U.S. trial of AstraZeneca's COVID-19 vaccine candidate, initially developed by the University of Oxford, remains on hold while regulators investigate an illness in one of the participants, even after a British study and other programmes outside of the United States have resumed.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Business